Articles tagged with: Daratumumab
A new year is upon us. I hope it has started well for everybody, and that all had a great holiday season!
The last few weeks of 2014 were a happening time for the multiple myeloma community. The short span of time witnessed the publication of updated criteria for the diagnosis of multiple myeloma from the International Myeloma Working Group (IMWG). In addition, the 56th annual meeting of the American Society of Hematology (ASH) took place in San Francisco, with literally hundreds of myeloma-related oral and poster presentations.
Therefore, it …
This past Sunday was the second day of the American Society of Hematology’s (ASH) annual meeting, which was held in San Francisco.
As on the first day of the meeting, myeloma-related presentations once again took place during several sessions throughout the day.
A myeloma-related education session held the first day of the conference was repeated once again on Sunday morning.
While the education session was being held, a separate “scientific symposium” with two oral presentations took place in parallel. The session focused on a novel immunotherapeutic approach to treating cancer …
The 2014 annual meeting of the American Society of Hematology (ASH) starts tomorrow, December 5, in San Francisco, and will continue until next Tuesday.
The ASH annual meeting is one of several large medical conferences where myeloma-related research findings are presented each year. However, from a multiple myeloma perspective, the ASH meeting is generally the most important of the meetings.
At this year’s meeting, for example, some 500 myeloma-presentations are scheduled to take place. The presentations will summarize current research on a wide range of topics, including the biology of …
It’s July, and we have had some time to digest the findings from the American Society of Clinical Oncology (ASCO) annual meeting held in Chicago May 30 through June 3.
Quite a few presentations caught one’s eye.
We finally saw the results of the much awaited PANORAMA-1 study investigating the efficacy and safety of panobinostat (LBH589) plus Velcade and dexamethasone compared to Velcade and dexamethasone alone.
Another study looked at …
This year’s annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago came to an end yesterday.
The fourth day of the meeting, which was Monday, was the busiest day in regard to myeloma-related research. It started with an oral presentation session that included seven talks about important new myeloma-related research. A poster session in the afternoon included several posters about myeloma-related research.
This article summarizes the most important findings from Monday’s oral presentation session. A later article will cover the findings from the afternoon poster session.